Pulmonx (NASDAQ:LUNG – Get Free Report) is one of 511 publicly-traded companies in the “Healthcare Equipment & Supplies” industry, but how does it contrast to its competitors? We will compare Pulmonx to similar businesses based on the strength of its risk, dividends, earnings, institutional ownership, valuation, analyst recommendations and profitability.
Earnings and Valuation
This table compares Pulmonx and its competitors top-line revenue, earnings per share and valuation.
| Gross Revenue | Net Income | Price/Earnings Ratio | |
| Pulmonx | $88.78 million | -$54.00 million | -2.83 |
| Pulmonx Competitors | $1.89 billion | $135.83 million | 5.76 |
Pulmonx’s competitors have higher revenue and earnings than Pulmonx. Pulmonx is trading at a lower price-to-earnings ratio than its competitors, indicating that it is currently more affordable than other companies in its industry.
Analyst Recommendations
This is a breakdown of recent recommendations for Pulmonx and its competitors, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Pulmonx | 1 | 0 | 3 | 0 | 2.50 |
| Pulmonx Competitors | 4311 | 10598 | 18392 | 838 | 2.46 |
Pulmonx presently has a consensus price target of $7.67, suggesting a potential upside of 168.25%. As a group, “Healthcare Equipment & Supplies” companies have a potential upside of 21.67%. Given Pulmonx’s stronger consensus rating and higher probable upside, equities analysts clearly believe Pulmonx is more favorable than its competitors.
Insider & Institutional Ownership
91.0% of Pulmonx shares are owned by institutional investors. Comparatively, 40.5% of shares of all “Healthcare Equipment & Supplies” companies are owned by institutional investors. 7.5% of Pulmonx shares are owned by company insiders. Comparatively, 14.9% of shares of all “Healthcare Equipment & Supplies” companies are owned by company insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a stock will outperform the market over the long term.
Volatility and Risk
Pulmonx has a beta of 0.19, meaning that its stock price is 81% less volatile than the S&P 500. Comparatively, Pulmonx’s competitors have a beta of 2.58, meaning that their average stock price is 158% more volatile than the S&P 500.
Profitability
This table compares Pulmonx and its competitors’ net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Pulmonx | -47.93% | -98.23% | -35.89% |
| Pulmonx Competitors | -270.28% | -155.47% | -22.38% |
Summary
Pulmonx competitors beat Pulmonx on 7 of the 13 factors compared.
Pulmonx Company Profile
Pulmonx is a medical technology company focused on minimally invasive treatments for people with severe emphysema, a form of chronic obstructive pulmonary disease (COPD). Its products are used by clinicians to evaluate patients and provide bronchoscopic treatment. The company’s Zephyr Endobronchial Valve is a small, one-way valve placed in the lungs through a bronchoscope. By reducing airflow to targeted areas of a diseased lung, the treatment is intended to help lessen lung hyperinflation and improve the function of healthier areas.
Receive News & Ratings for Pulmonx Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pulmonx and related companies with MarketBeat.com's FREE daily email newsletter.
